Revolutionising companion animal cancer care through accessible solutions

0 in 4

Dogs will develop cancer at some point during their lifetime

Of dogs aged 10 or older may develop cancer

Of deaths in dogs are reported to be caused by cancer

Of malignant bone tumours in dogs are osteosarcoma

We develop first-in-class cancer therapeutics
for companion animals.

Using translational models to accelerate clinical relevance and reduce development risk.

See how it all works

ValiRX Animal Health Pipeline

Our therapeutic assets are first-in-class within the veterinary oncology landscape, addressing unmet clinical needs with mechanisms and technologies not currently available in companion animal medicine.

Wireframe dog showing target tumour sites

Discovery

Optimisation

Pre-clinical

Phase 1

Phase 2

Phase 3

Osteosarcoma

(MG-002)

Hemangiosarcoma

(CLX001)

Cytolytix

Lymphoma

(MG-002)

Lymphoma

(3K Accelerator Strategy)

MG-002 is an eIF4A Helicase Inhibitor (small molecule)

CLX001 is an Oncolytic Peptide

3K Accelerator Strategy is small molecule based

Who we work with

We work alongside vets, pet parents and partners to turn comparative oncology into real-world treatments – for animals and for the people who cherish them.

Vets

• Clinical trials
• Patient Derived Samples
• Comparative Oncology collaborations

Pet parents

• Advocacy
• Clinical trial participation
• Future treatment opportunities

Partners

• Asset licensing
• Academic partnerships
• Commercial collaborations
• Co-development opportunities

Meet the team

Michelle Barnard

Chief scientific officer

For me, this only works if it’s done ethically, and that’s non-negotiable. Get that right, and the science can make a real difference for animals and humans alike.

Dr Mark Eccleston

Chief Executive Officer

I’ve seen first-hand how few treatment options exist for pets with cancer, and I’m determined to change that.

Melissa Barr

Chief Operating Officer

I believe that comparative oncology isn’t just about good science – it also means pets and people benefit from the same breakthroughs.

Why ValiRx Animal Health

Companion animals develop conditions that closely resemble those found in humans, making them not only patients in need of better treatment, but invaluable models for advancing medicine more broadly.

A great Dane with their head out the car window

Accelerate your out-licensing

We advance veterinary medicine through scientifically rigorous, ethically responsible development that prioritises better outcomes for companion animals while supporting broader translational progress.

Translational impact

We bridge veterinary and human medicine through comparative science, accelerating clinically meaningful discoveries that benefit both animal patients and future human therapies.

Scientific integrity

We maintain credibility, transparency, and precision in everything we do, ensuring our work is grounded in robust evidence and real-world relevance.

A dog is sitting in a park surrounded by leaves

Collaboration expertise

We work with leading scientific, clinical, and commercial partners to combine expertise, challenge thinking, and deliver stronger outcomes together.

Partner with us

Asset partners

Accelerate your in-licensing, academic innovation and commercialisation opportunities.

Veterinary collaborators

Join our network as a trial site, contribute samples, or collaborate on comparative oncology research.

Pet parent community

Help raise awareness, advocate for better treatment options, and connect pets with clinical trials.

Get in touch to learn more

Get in touch